Quantum Cyber exits colorectal business, pivots to pancreatic screening and cybersecurity

Filed May 15, 2026 · Period ending March 31, 2026 · ~1 min read

Key Changes

• high

  Company disclosed material weakness in financial controls: inadequate policies, poor documentation, and improper system access. Historical misstatements were corrected before issuance, but weakness creates risk of undetected errors.

  Controls & Procedures verify on EDGAR →
• high

  Substantial doubt about ability to continue as going concern. $110M accumulated deficit, recurring losses, and $2.7M negative operating cash flow in Q1. Management believes current $4.8M cash plus future financing may cover one year, but uncertainty remains.

  MD&A: Liquidity verify on EDGAR →
• high

  Strategic pivot announced alongside workforce termination (all German subsidiary employees), $2.6M IP impairment, and sale of legacy colorectal assets for $1.6M total. Company rebranded from Mainz Biomed to Quantum Cyber, installed new CEO, and announced expansion into post-quantum cybersecurity.

  MD&A: Business Strategy verify on EDGAR →